论文部分内容阅读
为评价思密达口服防治新生儿高胆的效果,对60名高胆新生儿进行了研究.对照组30例用消黄灵加蓝光治疗,实验组除上述治疗外,加思密达1g,一日3次加水冲服.结果:两组高胆新生儿一周治愈率,实验组为96．67%,参照组为60%(P＝0．0001),蓝光治疗时间,实验组较对照组明显缩短(P＝0．0092).结果提示,思密达是防治新生儿高胆安全、有效、经济、方便的辅助治疗药物.
In order to evaluate the effect of Smectite orally in preventing and treating neonatal hyperbilirubinemia, 60 hyperbilirubinectants were studied.30 cases in the control group were treated with Xiaohuangling plus blue light, except for the above treatment, gasemectin 1g, Three times a day with water and blunt .Results: Two groups of high-biliary neoplasms one week cure rate, the experimental group was 96.67%, the reference group was 60% (P = 0.0001), blue light treatment time, the experimental group than the control group (P = 0.0092) .The results suggest that Smecta is a safe, effective, economical and convenient adjuvant therapy for preventing and treating neonatal hypercholesterolemia.